Post

New research · Ophthalmology
Immunity, inflammation and disease · 13h
Cohort studyImmunity, inflammation and disease · 2026

Impact of Early COVID-19 Antiviral Therapy on the Incidence of Uveitis: A Retrospective Cohort Study Using the TriNetX Database.

Hou-Ting Kuo, Alan Y Hsu, De-Yi Liu … Yi-Yu Tsai
Read paper
OphthalmologyCohort study

Early COVID-19 antiviral therapy associated with lower risk of new-onset uveitis.

Impact of Early COVID-19 Antiviral Therapy on the Incidence of Uveitis: A Retrospective Cohort Study Using the TriNetX Database.

Hou-Ting Kuo … Yi-Yu Tsai
Immunity, inflammation and disease · 2026
Purpose

To assess whether antivirals are associated with a reduced incidence of uveitis following COVID-19.

Methods

Who received antiviral agents (Paxlovid, Molnupiravir, or Remdesivir) within 5 days of diagnosis were matched 1:1 with untreated controls using propensity score matching.

n = 438,455 patients
Results

early antiviral treatment lowered the chance of developing new eye inflammation

HR by subgroup · 95% CI
null = 1
uveitis at 3 months
0.62
6 months
0.68
1 year
0.76
3 years
0.80
all duration
0.81
More results

Subgroup analysis revealed consistent benefit across all age groups, with females experiencing greater protection than males.

Significant reductions in uveitis risk were observed among patients with diabetes (HR = 0.68, 95% CI: 0.52-0.89), hyperlipidemia (HR = 0.78, 95% CI: 0.65-0.95), and heart failure (HR = 0.52, 95% CI: 0.30-0.90).

More results

Among the antivirals, Paxlovid was associated with a significant risk reduction (HR = 0.83, 95% CI: 0.71-0.96), whereas Molnupiravir and Remdesivir showed no statistically significant effect.

Besides, the risk reduction was evident regardless of prior COVID-19 vaccination status.

“
Conclusion · 1 of 2

Early antiviral treatment for COVID-19 such as Paxlovid, is associated with a reduced risk of uveitis.

Conclusion · 2 of 2

These findings suggest that, in addition to mitigating systemic disease progression, antiviral therapy may confer ocular protective effects, which could be especially meaningful for high-risk populations.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
AI / Informatics
0·962 for OCT
MerMED-FM was very accurate at diagnosing diseases using eye scans
AI / Informatics
0.98
Artificial intelligence's eyelid-height measurements matched doctors' manual measurements almost perfectly
AI / Informatics
92.1%
combining eye scans and photos correctly told benign from cancerous lesions apart nearly every time
Cohort Study
28.6%
recurred locally in more than 1 in 4 patients over years of follow-up
Cohort Study
-0.395
excision group's post-op eyelid fullness score was lower - greater improvement
Cohort Study
86.7%
of infants probed after 12 months still had unresolved tear duct blockage
Observational
16%
eyelid tissue in rosacea patients showed less of this key repair-signaling protein inside cell nuclei
Cohort Study
25%
about 1 in 4 treated cases had symptoms return after improving